AIM ImmunoTech's Ampligen Shows Favorable Safety Profile In Early-Stage COVID-19 Study

Comments
Loading...
  • AIM ImmunoTech Inc AIM has completed the dosing of Cohort 1 in Phase 1 study on the safety of Ampligen as an intranasal therapy, as potential prophylaxis or treatment for COVID-19 and other respiratory viral diseases.
  • The company reported no serious adverse events, thus paving the way for dose escalation in Cohort 2.
  • An independent institute in the Netherlands is conducting the clinical study AMP-COV-100 (CHDR2049) to evaluate the safety and activity of repeated intranasal administration of Ampligen in Healthy Subjects.
  • AIM is the sponsor and is funding the clinical study.
  • The study protocol calls for the enrollment of eight healthy subjects in each of four Cohorts to receive Ampligen. Two additional healthy subjects in each Cohort will receive a placebo for a total of 40 healthy subjects.
  • AIM will continue to provide interim updates on the clinical trial.
  • Price Action: AIM shares were trading 0.65% higher at $2.34 during market trading hours on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs

Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!